Equities

Deltex Medical Group PLC

DTXMF:PKC

Deltex Medical Group PLC

Actions
  • Price (USD)0.0013
  • Today's Change0.00 / 0.00%
  • Shares traded55.00k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Apr 03 2024 19:07 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Deltex Medical Group Plc is a United Kingdom-based medical device company. The Company develops, manufactures and distributes a hemodynamic monitoring technology. The Company's TrueVue platform offers three monitoring technologies, such as Oesophageal Doppler Monitoring (ODM+), Pulse Pressure Waveform Analysis (PPWA) and High Definition Impedance CardioGraphy (HD-ICG). Its ODM+ is a fluid management and cardiac output monitoring technology to directly measure both flow and pressure in adults and pediatrics. HD-ICG provides continuous and sensitive measurements of cardiac output and other hemodynamic parameters. The system is stabilized using HD-Z signal filter technology. HD-ICG disposable electrodes are placed on the neck and chest. PPWA uses the researched pulse pressure wave algorithm, which is available to derive hemodynamic parameters, calibrated from the Doppler. Its applications include surgery, acute kidney injury, enhanced recovery, paediatric, and COVID-19 critical care.

  • Revenue in GBP (TTM)1.78m
  • Net income in GBP-1.28m
  • Incorporated2000
  • Employees37.00
  • Location
    Deltex Medical Group PLCTerminus RoadCHICHESTER PO19 8TXUnited KingdomGBR
  • Phone+44 124 377 4837
  • Fax+44 124 353 2534
  • Websitehttps://www.deltexmedical.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.